Literature DB >> 7815103

Recording neurological impairment in clinical trials of glioma.

R Grant1, J Slattery, A Gregor, I R Whittle.   

Abstract

The criteria for clinical response to treatment in cerebral glioma remain poorly defined, but could be made more objective if simple measures of neurological impairments were included in the definitions. We assessed the utility of simple fast previously validated tests of limb impairment (Timed nine hole peg test and 10 meter walk), memory (Williams delayed recall test) and language (Boston Aphasia Severity Rating Scale) in fifty patients with primary brain tumours to see if they could act as a surrogate for neurological impairment. The tests were compared with established measures of physical disability (Barthel Disability Index [BDI]) and handicap. Timed tests of hand function and gait were sensitive to minor impairments and were abnormal in patients with physical disability on BDI. Timed tests correlated well with handicap (rank correlation 0.734). Short term memory was impaired more commonly with tumours involving the left hemisphere (p < 0.01). Dysphasia limited testing of memory in 8%. Depression was associated with problems in limb function (p < 0.01), memory (p < 0.001), language (p < 0.001), BDI (p < 0.001) and handicap (p < 0.001). The number of abnormal fast tests also correlated with the severity of handicap (rank correlation 0.786) indicating that memory impairment and aphasia contribute to handicap and should be assessed. Median time to complete all assessments was 7 minutes 20 seconds. Utilization of these simple tests will add sensitivity and objectivity to evaluation of neurological response in clinical trials and can be performed quickly by non medical staff.

Entities:  

Mesh:

Year:  1994        PMID: 7815103     DOI: 10.1007/bf01051047

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  Establishing the limits of the Mini-Mental State. Examination of 'subtests'.

Authors:  E P Feher; R K Mahurin; R S Doody; N Cooke; J Sims; F J Pirozzolo
Journal:  Arch Neurol       Date:  1992-01

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Loss of arm function after stroke: measurement, frequency, and recovery.

Authors:  V M Parker; D T Wade; R Langton Hewer
Journal:  Int Rehabil Med       Date:  1986

5.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

Authors:  M P Amato; L Fratiglioni; C Groppi; G Siracusa; L Amaducci
Journal:  Arch Neurol       Date:  1988-07

6.  Interrater reliability of the NIH stroke scale.

Authors:  L B Goldstein; C Bertels; J N Davis
Journal:  Arch Neurol       Date:  1989-06

7.  Arm function after stroke: measurement and recovery over the first three months.

Authors:  A Heller; D T Wade; V A Wood; A Sunderland; R L Hewer; E Ward
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02

10.  Phase II study of tauromustine in malignant glioma.

Authors:  A Gregor; R Rampling; M Aapro; P Malmström; I R Whittle; R Rye; M Stewart; R Sellar; B Demierre; J W Ironside
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

View more
  22 in total

1.  Use of different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation of time to progression: reanalysis of the MRC BR2 study.

Authors:  J Chataway; S Stenning; N Bleehen; R Grant
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  Cognitive functioning in newly presenting patients with supratentorial intracranial tumors: is there a role for inspection time?

Authors:  Jennifer L Scotland; Ian R Whittle; Ian J Deary
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 3.  Review on quality of life issues in patients with primary brain tumors.

Authors:  Martin J B Taphoorn; Eefje M Sizoo; Andrew Bottomley
Journal:  Oncologist       Date:  2010-05-27

4.  Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.

Authors:  Birgit Flechl; Michael Ackerl; Cornelia Sax; Karin Dieckmann; Richard Crevenna; Alexander Gaiger; Georg Widhalm; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-29       Impact factor: 4.130

5.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

6.  Cognitive effects of tumour and surgical treatment in glioma patients.

Authors:  Andrea Talacchi; Barbara Santini; Silvia Savazzi; Massimo Gerosa
Journal:  J Neurooncol       Date:  2010-09-28       Impact factor: 4.130

7.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

8.  Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.

Authors:  Guy Pelletier; Marja J Verhoef; Nasreen Khatri; Neil Hagen
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

9.  Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not.

Authors:  Robert Grant; Mark Walker; Donald Hadley; Tina Barton; Chester Osborn
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

10.  Prediction of neurocognitive outcome in adult brain tumor patients.

Authors:  Thomas A Kaleita; David K Wellisch; Timothy F Cloughesy; Judith M Ford; Donald Freeman; Thomas R Belin; Jeffrey Goldman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.